NASDAQ:GERN

Geron Stock Forecast, Price & News

$1.51
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.49
Now: $1.51
$1.54
50-Day Range
$1.42
MA: $1.68
$1.89
52-Week Range
$1.10
Now: $1.51
$2.40
Volume1.76 million shs
Average Volume3.70 million shs
Market Capitalization$480.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700
Employees53
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.68 per share

Profitability

Net Income$-68,550,000.00
Net Margins-21,631.02%

Miscellaneous

Market Cap$480.98 million
Next Earnings Date5/27/2021 (Estimated)
OptionableOptionable

Headlines

Geron (NASDAQ:GERN) Rating Reiterated by HC Wainwright
April 8, 2021 |  americanbankingnews.com
Form DEF 14A GERON CORP For: May 11 - StreetInsider.com
March 23, 2021 |  streetinsider.com
Geron: Hurdles Ahead (NASDAQ:GERN) - Seeking Alpha
March 18, 2021 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

637th out of 2,021 stocks

Pharmaceutical Preparations Industry

299th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$1.51
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron
or view top-rated stocks.

What stocks does MarketBeat like better than Geron?

Wall Street analysts have given Geron a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Geron wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Geron?

Geron saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 27,550,000 shares, a drop of 23.4% from the March 15th total of 35,950,000 shares. Based on an average daily volume of 3,830,000 shares, the short-interest ratio is currently 7.2 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, May 27th 2021.
View our earnings forecast for Geron
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its earnings results on Wednesday, March, 10th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.08 million. Geron had a negative trailing twelve-month return on equity of 43.76% and a negative net margin of 21,631.02%. During the same period in the prior year, the firm posted ($0.15) EPS.
View Geron's earnings history
.

How has Geron's stock price been impacted by Coronavirus?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GERN shares have increased by 46.6% and is now trading at $1.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GERN?

5 Wall Street analysts have issued 1 year price objectives for Geron's shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Geron's stock price to reach $4.20 in the next year. This suggests a possible upside of 178.1% from the stock's current price.
View analysts' price targets for Geron
or view top-rated stocks among Wall Street analysts.

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 70, Pay $1.39M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 52, Pay $761.54k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 57, Pay $791.52k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 57, Pay $764.81k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 46, Pay $892.29k)
  • Ms. Suzanne Messere, Head of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 71)
  • Ms. Shannon Odam, VP of HR
  • Mr. Anil Kapur, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 51)

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.51.

How much money does Geron make?

Geron has a market capitalization of $480.98 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Geron have?

Geron employs 53 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

Where are Geron's headquarters?

Geron is headquartered at 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.